A class of migraine drugs targeting calcitonin gene-related peptide, or CGRP, is now outperforming the older medications that neurologists have relied on for decades. In the landmark HER-MES study, 55.4% of patients taking erenumab (brand name Aimovig) achieved at least a 50% reduction in monthly migraine days, compared to just 31.2% on topiramate, one of the most commonly prescribed traditional preventives. That gap is not subtle. It represents a meaningful difference in how many days per month a person can function without debilitating head pain — and it came with fewer side effects. In March 2024, the American Headache Society made it official: CGRP-targeting therapies should be considered first-line for migraine prevention, ending the long-standing requirement that patients fail older drug classes before gaining access to these newer options.
For the estimated one billion people worldwide who live with migraine — and for the millions of older adults managing migraine alongside cognitive decline, cardiovascular disease, or depression — this shift matters. Migraine is not just a headache. It is a neurological condition linked to increased dementia risk and reduced quality of life, particularly in aging populations. The arrival of eight FDA-approved CGRP drugs, spanning injectable monoclonal antibodies, oral tablets, and even a nasal spray, has changed the treatment landscape in ways that directly affect brain health planning. This article breaks down what CGRP drugs are and how they work, examines the clinical evidence behind their superiority over older treatments, addresses safety concerns including a recent FDA labeling update in March 2025, and explores what these medications cost, who can access them, and what the future holds for migraine care.
Table of Contents
- What Are CGRP Drugs and Why Are They Outperforming Older Migraine Treatments?
- How Strong Is the Clinical Evidence Behind CGRP Therapies?
- The Safety Picture, Including a Major 2025 FDA Update
- How Do CGRP Drugs Compare to Each Other and to Triptans in Practice?
- The Cost Problem and Access Barriers
- CGRP Drugs Now Reach Younger Patients Too
- Where Migraine Treatment Is Headed
- Conclusion
- Frequently Asked Questions
What Are CGRP Drugs and Why Are They Outperforming Older Migraine Treatments?
CGRP is a protein that spikes during migraine attacks and plays a central role in the pain signaling and blood vessel dilation that drive migraine symptoms. Unlike older preventives such as topiramate, beta-blockers, or antidepressants — which were all borrowed from other medical fields and repurposed for migraine — CGRP therapies were designed from the ground up to target the migraine mechanism itself. That precision is the core reason they perform better. The four monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) block CGRP or its receptor through monthly or quarterly injections. The three oral gepants (rimegepant, ubrogepant, and atogepant) and one nasal spray gepant (zavegepant, sold as Zavzpret) work as small-molecule CGRP antagonists that can be taken as needed or daily. The practical difference between these drugs and triptans — the previous gold standard for acute migraine — goes beyond efficacy numbers. Triptans constrict blood vessels, which makes them risky or outright contraindicated for patients with heart disease, stroke history, or uncontrolled hypertension.
For older adults, who disproportionately carry those cardiovascular risk factors, triptans have always been a problematic option. CGRP drugs do not constrict blood vessels. Large randomized trials involving more than 10,000 patients have shown no overall increase in cardiovascular or cerebrovascular risk with CGRP monoclonal antibodies or gepants in lower-risk populations. That safety profile opens treatment doors that were previously closed for a significant portion of the aging population. Another advantage is versatility. Gepants like rimegepant (Nurtec ODT) can serve double duty as both an acute treatment when a migraine strikes and a preventive taken on a regular schedule. Triptans can only be used acutely. For someone managing multiple medications — a common reality for older adults — consolidating acute and preventive migraine treatment into a single drug simplifies their regimen and reduces the risk of drug interactions.
How Strong Is the Clinical Evidence Behind CGRP Therapies?
The evidence base is substantial and growing. The American Headache Society’s 2024 position statement, published on March 11, 2024, was informed by more than 150 new clinical and real-world studies — a body of evidence the AHS described as one that “vastly exceeds that for any other preventive treatment approach.” Across studies, CGRP monoclonal antibodies reduce monthly migraine days by half in 27.6% to 61.4% of patients, a wide range that reflects variation in study populations but consistently shows meaningful benefit. For chronic migraine sufferers — those experiencing 15 or more headache days per month — the results are particularly striking. Research has shown that 40.88% of chronic migraine patients converted to episodic migraine status while on CGRP therapy, crossing a clinical threshold that dramatically changes daily life. Among patients trapped in the cycle of medication overuse headache, where taking too many acute medications paradoxically worsens headaches, between 29% and 88% were able to stop overusing medications on CGRP treatment.
Emerging research on dual-CGRP therapy, which combines two different CGRP mechanisms, found a 20% reduction in headache severity compared to 10% with a single CGRP drug — suggesting that combining approaches within this class may offer additional benefit for treatment-resistant cases. However, these numbers come with important caveats. Not every patient responds. Roughly 40% to 70% of patients in some studies did not reach the 50% migraine-day reduction threshold, meaning a substantial minority sees limited benefit. Clinicians generally recommend a three-to-six-month trial period before concluding that a particular CGRP drug is not working, and switching between different drugs in the class sometimes yields better results. For patients with dementia or cognitive impairment, the challenge of tracking migraine frequency accurately enough to assess treatment response adds another layer of complexity — caregivers play a critical role in monitoring outcomes.
The Safety Picture, Including a Major 2025 FDA Update
In March 2025, the FDA updated safety labeling for all CGRP monoclonal antibodies and gepants to include the potential for developing or worsening hypertension and Raynaud’s phenomenon, a condition involving reduced blood flow to the fingers and toes. Erenumab specifically received additional labeling for constipation, a side effect that had been well-documented in clinical practice. These labeling changes do not mean the drugs are unsafe, but they do require attention — particularly for older adults who may already be managing blood pressure issues or circulatory problems. A real-world study published in Neurology in 2025 found that initiating a CGRP inhibitor was associated with a modestly increased risk of cardiovascular events and ischemic stroke compared to not starting treatment. Critically, this signal appeared in higher-risk populations — people who already had elevated cardiovascular risk factors.
For lower-risk patients, the large randomized trial data involving more than 10,000 participants continues to show no significant increase in cardiovascular or cerebrovascular events. The takeaway for patients and their doctors is nuanced: for someone with well-controlled blood pressure and no heart disease history, the cardiovascular risk appears minimal. For someone with multiple vascular risk factors, the decision warrants a careful conversation weighing migraine burden against potential cardiovascular concerns. On the positive side of the safety ledger, a new randomized trial found that fremanezumab (Ajovy) reduced comorbid depressive symptoms in people with migraine. Given the well-established links between migraine, depression, and cognitive decline in older adults, a treatment that addresses both pain and mood has real clinical appeal for the brain health community.
How Do CGRP Drugs Compare to Each Other and to Triptans in Practice?
Within the CGRP class, the choice between a monoclonal antibody and a gepant often comes down to patient preference and clinical circumstances. The monoclonal antibodies — Aimovig, Ajovy, Emgality, and Vyepti — are administered by injection (monthly or quarterly self-injection for most, intravenous infusion for Vyepti). They tend to be used purely for prevention. The gepants — Nurtec ODT, Ubrelvy, Qulipta, and Zavzpret — are taken orally or, in the case of Zavzpret, as a nasal spray. Their ability to serve as both acute and preventive treatments gives them flexibility that the antibodies lack.
Zavzpret’s nasal spray delivery is particularly useful for patients who experience nausea or vomiting during attacks and cannot reliably swallow a pill. Compared to triptans, gepants have demonstrated lower emergency department utilization and fewer parenteral migraine treatments (injections or IV medications given in urgent care settings) in propensity-matched analyses. This suggests that gepants may do a better job of keeping patients out of the ER — a meaningful outcome measure for both patient quality of life and healthcare costs. However, triptans remain effective for many patients, cost a fraction of what CGRP drugs cost (most are available as inexpensive generics), and have decades of safety data behind them. For patients without cardiovascular risk factors who respond well to triptans, there is no clinical imperative to switch. The case for CGRP drugs is strongest when triptans are contraindicated, ineffective, or poorly tolerated — or when a patient needs a preventive medication and wants to avoid the cognitive side effects of topiramate, a drug notorious for causing memory problems and mental fogginess that older adults can ill afford.
The Cost Problem and Access Barriers
Injectable CGRP monoclonal antibodies carry a list price of approximately $1,000 or more per month, and no generics are currently available. The CGRP antibody segment accounted for 56.68% of the migraine drugs market revenue in 2024, and combined sales are expected to reach $4 billion by 2026 within a global migraine drugs market estimated at $7.6 billion in 2025 and projected to hit $8.43 billion in 2026. These are blockbuster-level drugs, and their pricing reflects it. For patients, particularly older adults on fixed incomes or Medicare, the cost can be prohibitive.
Most manufacturers offer copay assistance programs for commercially insured patients, but these programs typically exclude Medicare beneficiaries. Prior authorization requirements remain common, and some insurers still require documentation of failed trials on cheaper alternatives before approving CGRP therapy — even though the American Headache Society’s 2024 position statement explicitly argues against step therapy requirements. The gap between what the clinical guidelines recommend and what insurance will pay for remains one of the biggest practical barriers to accessing these drugs. Patients and caregivers navigating this landscape should request a benefits investigation through their prescriber’s office, contact manufacturer patient assistance programs directly, and consider whether an oral gepant like atogepant (Qulipta) might have different formulary placement than an injectable antibody on their specific plan. Coverage varies widely, and persistence with the appeals process can sometimes make the difference.
CGRP Drugs Now Reach Younger Patients Too
On August 6, 2025, the FDA approved an expanded indication for fremanezumab (Ajovy) to include preventive treatment of pediatric patients aged 6 to 17 weighing at least 45 kilograms with episodic migraine. This was a significant milestone — it marked one of the first CGRP therapies to receive a pediatric indication, addressing a population that had been largely left out of the CGRP revolution.
While this development is outside the typical age range of a brain health and dementia care audience, it matters to grandparents and caregivers who may be managing migraine in younger family members while dealing with their own neurological conditions. Migraine often runs in families, and understanding the full treatment landscape helps caregivers advocate for multiple generations.
Where Migraine Treatment Is Headed
The trajectory is clear: CGRP-targeted therapies are becoming the backbone of modern migraine care, and the next frontier involves optimizing how they are used rather than questioning whether they work. Dual-CGRP therapy — combining medications that target different parts of the CGRP pathway — is showing early promise with greater reductions in headache severity. New delivery methods like zavegepant’s nasal spray point toward faster-onset options that bypass the GI tract entirely. Meanwhile, the FDA’s 2025 approval of AXS-07, a combination of meloxicam and rizatriptan using MoSEIC rapid-absorption technology, shows that innovation is also continuing outside the CGRP class.
For the brain health community, the migraine-dementia connection gives these advances added weight. Poorly controlled migraine is associated with white matter lesions, cerebrovascular changes, and increased dementia risk over time. Treatments that effectively reduce migraine frequency and severity are not just improving today’s quality of life — they may be protecting long-term cognitive health. As the evidence base continues to grow and access barriers slowly fall, CGRP drugs are positioned to become as routine in neurology as statins are in cardiology.
Conclusion
CGRP-targeted therapies represent the most significant advance in migraine treatment in decades. With eight FDA-approved drugs spanning injections, pills, and nasal sprays, clinical evidence from more than 150 studies, and a first-line recommendation from the American Headache Society, these medications have moved from promising newcomers to the standard of care. Their advantages over older treatments — superior efficacy, no blood vessel constriction, dual acute-and-preventive capability, and an emerging signal for improving comorbid depression — make them particularly relevant for older adults managing migraine alongside cardiovascular risk and cognitive concerns.
The picture is not without complications. The March 2025 FDA safety labeling update, the high monthly cost, insurance access barriers, and the reality that not every patient responds all demand honest conversations between patients and their clinicians. But for the millions of people whose migraines have been inadequately controlled by older medications, or who were told they could not safely use triptans, CGRP drugs offer something genuinely new: a treatment designed specifically for their condition, backed by robust evidence, and increasingly recognized as the place to start rather than the last resort.
Frequently Asked Questions
Are CGRP drugs safe for people with heart disease?
CGRP drugs do not constrict blood vessels like triptans, and large trials with over 10,000 patients show no overall cardiovascular risk increase in lower-risk populations. However, a 2025 real-world study found a modestly increased risk of cardiovascular events in higher-risk populations, and the FDA updated labeling in March 2025 to include potential for worsening hypertension. Patients with significant cardiovascular risk factors should discuss the tradeoffs with their doctor.
Can I take a CGRP drug and a triptan together?
In many cases, yes. Some patients use a CGRP monoclonal antibody for prevention and a triptan for acute attacks. However, combining a gepant with a triptan requires medical guidance since both act on related pathways. Your neurologist can advise on safe combinations based on your specific health profile.
How long does it take to know if a CGRP drug is working?
Most clinicians recommend a trial of three to six months before concluding a CGRP drug is ineffective. Some patients notice improvement within the first month, but the full benefit often develops gradually. If one CGRP drug does not work, switching to a different one in the class sometimes produces a better response.
Will Medicare cover CGRP medications?
Medicare Part D plans may cover CGRP drugs, but prior authorization and step therapy requirements are common. Manufacturer copay assistance programs typically exclude Medicare patients, though some offer separate patient assistance programs for those who qualify financially. Persistence with appeals and working with your prescriber’s office on documentation can improve the chances of approval.
Is there a connection between migraines and dementia risk?
Research has linked poorly controlled migraine to white matter lesions, cerebrovascular changes, and an elevated risk of cognitive decline over time. While CGRP drugs have not been studied specifically for dementia prevention, effectively reducing migraine frequency and severity may help protect long-term brain health by reducing the cumulative neurological burden of repeated attacks.
What is the newest CGRP drug available?
Zavegepant (Zavzpret), an intranasal CGRP antagonist, is among the newest additions, offering fast-onset relief without needing to swallow a pill. In August 2025, fremanezumab (Ajovy) also received an expanded approval for pediatric patients aged 6 to 17 with episodic migraine. Additionally, AXS-07, a non-CGRP combination drug using rapid-absorption technology, was approved for acute migraine treatment.
